A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (MK-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Crizotinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 04 Apr 2017 Planned End Date changed from 1 Sep 2020 to 7 Oct 2019.
- 04 Apr 2017 Planned primary completion date changed from 1 Sep 2020 to 7 Oct 2019.